Angiotensin–neprilysin inhibition confers renoprotection in rats with diabetes and hypertension by limiting podocyte injury
E Uijl, DC't Hart, LCW Roksnoer… - Journal of …, 2020 - journals.lww.com
Objectives: Combined angiotensin receptor--neprilysin inhibition (ARNI) reduces
glomerulosclerosis better than single angiotensin receptor blockade (ARB) in diabetic …
glomerulosclerosis better than single angiotensin receptor blockade (ARB) in diabetic …
Blood pressure-independent renoprotection in diabetic rats treated with AT1 receptor–neprilysin inhibition compared with AT1 receptor blockade alone
LCW Roksnoer, R van Veghel… - Clinical …, 2016 - portlandpress.com
ARNI [dual AT1 (angiotensin II type 1) receptor–neprilysin inhibition] exerts beneficial effects
on blood pressure and kidney function in heart failure, compared with ARB (AT1 receptor …
on blood pressure and kidney function in heart failure, compared with ARB (AT1 receptor …
Valsartan slows the progression of diabetic nephropathy in db/db mice via a reduction in podocyte injury, and renal oxidative stress and inflammation
G Zhou, AK Cheung, X Liu, Y Huang - Clinical science, 2014 - portlandpress.com
Higher doses of AngII (angiotensin II) blockers are intended to optimize albuminuria
reduction rather than for blood pressure control in chronic kidney disease. However, the …
reduction rather than for blood pressure control in chronic kidney disease. However, the …
Unlike each drug alone, lisinopril if combined with avosentan promotes regression of renal lesions in experimental diabetes
E Gagliardini, D Corna, C Zoja… - American journal …, 2009 - journals.physiology.org
In the present study, we evaluated the effect of simultaneously blocking angiotensin II
synthesis and endothelin (ET)-1 activity as a multimodal intervention to implement …
synthesis and endothelin (ET)-1 activity as a multimodal intervention to implement …
Adding a statin to a combination of ACE inhibitor and ARB normalizes proteinuria in experimental diabetes, which translates into full renoprotection
C Zoja, D Corna, E Gagliardini… - American Journal …, 2010 - journals.physiology.org
The capacity of renin-angiotensin system (RAS) inhibitors to delay progression of diabetic
nephropathy depends on the time at which therapy is started. A multimodal intervention is …
nephropathy depends on the time at which therapy is started. A multimodal intervention is …
[HTML][HTML] Efficacy of aliskiren, compared with angiotensin II blockade, in slowing the progression of diabetic nephropathy in db/db mice: should the combination therapy …
G Zhou, X Liu, AK Cheung, Y Huang - American Journal of …, 2015 - ncbi.nlm.nih.gov
Although the intensive use of angiotensin II blockade (ACEI or ARB), progression of diabetic
nephropathy is common. A feedback increase in renin production often accompanies …
nephropathy is common. A feedback increase in renin production often accompanies …
Nilvadipine attenuates mesangial expansion and glomerular hypertrophy in diabetic db/db mice, a model for type 2 diabetes
T Moriyama, K Oka, H Ueda, E Imai - Journal of Clinical and Experimental …, 2004 - Springer
Background The renoprotection achieved by angiotensin II blockade in the treatment of
diabetic nephropathy is well established in both the clinical and the experimental settings. In …
diabetic nephropathy is well established in both the clinical and the experimental settings. In …
Renoprotective and anti‐hypertensive effects of combined valsartan and perindopril in progressive diabetic nephropathy in the transgenic (mRen‐2) 27 rat
JL Wilkinson‐Berka, NJ Gibbs… - Nephrology Dialysis …, 2001 - academic.oup.com
Background. We have previously reported that severe glomerulosclerosis progressively
develops in the streptozotocin (STZ) diabetic transgenic (mRen‐2) 27 rat. In this diabetic …
develops in the streptozotocin (STZ) diabetic transgenic (mRen‐2) 27 rat. In this diabetic …
Targeting reduction of proteinuria in glomerulonephritis: Maximizing the antifibrotic effect of valsartan by protecting podocytes
C Gu, G Zhou, NA Noble, WA Border… - Journal of the Renin …, 2014 - journals.sagepub.com
Although angiotensin (Ang) II blockade has become a standard antifibrotic therapy in kidney
disease, the therapeutic efficacy of Ang II blockade is yet to be optimized. Considering the …
disease, the therapeutic efficacy of Ang II blockade is yet to be optimized. Considering the …
Protective effects of aliskiren and valsartan in mice with diabetic nephropathy
Aim: We investigated whether aliskiren, a direct renin inhibitor, provided protection in a
model of diabetic nephropathy in mice and compared its protective effects to valsartan, an …
model of diabetic nephropathy in mice and compared its protective effects to valsartan, an …